The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Current Therapeutic Research - Clinical and Experimental

Volumn 75, Issue , 2013, Pages 88-92

  Wang, Hua ^a   Ni, Yafang ^a   Yang, Shuo ^a   Li, Huizhi ^a   Li, Xu ^a   Feng, Bo ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Body composition; Fat distribution; Monodrug therapy; Newly diagnosed type 2 diabetes

Indexed keywords

ACARBOSE; ADIPONECTIN; CHOLESTEROL; GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; LEPTIN; LIPID; METFORMIN; TRIACYLGLYCEROL;

ABDOMEN; ABDOMINAL FAT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE;

EID: 84890155190     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2013.10.002     Document Type: Article

References (21)

1. Barnett A., Allsworth J., Jameson K., et al. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007, 23:1493-1507.
2. Nichols G.A., Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007, 9:96-102.
3. Hermansen K., Mortensen L.S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007, 30:1127-1142.
4. Dervaux N., Wubuli M., Megnien J.L., et al. Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects. Atherosclerosis 2008, 201:413-417.
5. Schütt M., Kern W., Zimmermann A., et al. Association of antidiabetic therapies to glycemic control and to body weight in type 2 diabetes: a German multicenter analysis on 9294 patients. Exp Clin Endocrinol Diabet 2010, 118:490-495.
6. Janghorbani M., Amini M., Salehi-Marzijarani M. Weight change, blood pressure, lipids and glycemic control among patients with type 2 diabetes. Ann Nutr Metab 2011, 58:141-149.
7. Lee C.G., Boyko E.J., Barrett-Connor E., et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 2011, 34:2381-2386.
8. Rodríguez-Moctezuma J.R., Robles-López G., López-Carmona J.M., et al. Effect of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab 2005, 7:189-192.
9. Ripsin C.M., Kang H., Urban R.J. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 2009, 79:29-36.
10. Helou R. Should we continue to use the Cockcroft-Gault formula?. Nephron Clin Pract 2010, 116:c172-c185.
11. Yoshizumi T., Nakamura T., Yamane M., et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999, 211:283-286.
12. Ridderstråle M., Gudbjörnsdottir S., Eliasson B., et al. Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006, 259:314-322.
13. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 2010, 10:306-315.
14. Palmer A.J., Roze S., Valentine W.J., et al. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Curr Med Res Opin 2004, 20(Suppl 1):S67-S73.
15. Sun G., French C.R., Martin G.R., et al. Comparison of multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for assessment of percentage body fat in a large, healthy population. Am J Clin Nutr 2005, 81:74-88.
16. Plank L.D. Dual-energy X-ray absorptiometry and body composition. Curr Opin Clin Nutr Metab Care 2005, 8:305-309.
17. Beeson W.L., Batech M., Schultz E., et al. Comparison of body composition by bioelectrical impedance analysis and dual-energy X-ray absorptiometry in Hispanic diabetics. Int J Body Compos Res 2010, 8:45-50.
18. Shuster A., Patlas M., Pinthus J.H., et al. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol 2012, 85:1-10.
19. Lahmann P.H., Lissner L., Gullberg B., et al. A prospective study of adiposity and all-cause mortality: the Malmö Diet and Cancer Study. Obes Res 2002, 10:361-369.
20. Romero-Corral A., Somers V.K., Sierra-Johnson J., et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 2010, 31:737-746.
21. Heitmann B.L., Erikson H., Ellsinger B.M., et al. Mortality associated with body fat, fat-free mass and body mass index among 60-year-old Swedish men-a 22-year follow-up. The study of men born in 1913. Int J Obes Relat Metab Disord 2000, 24:33-37.